Analyst Price Targets — NUVB
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| January 27, 2026 1:20 pm | — | Truist Financial | $13.00 | $5.66 | TheFly | Nuvation Bio price target raised to $13 from $11 at Truist |
| January 21, 2026 11:35 am | Leonid Timashev | RBC Capital | $12.00 | $6.01 | TheFly | Nuvation Bio price target raised to $12 from $9 at RBC Capital |
| January 12, 2026 1:51 pm | — | H.C. Wainwright | $17.00 | $6.52 | TheFly | Nuvation Bio price target lowered to $17 from $18 at H.C. Wainwright |
| January 7, 2026 5:45 am | Michael Yee | UBS | $10.00 | $8.49 | StreetInsider | UBS Starts Nuvation Bio Inc (NUVB) at Neutral |
| December 11, 2025 11:25 am | — | H.C. Wainwright | $18.00 | $7.89 | TheFly | Nuvation Bio price target raised to $18 from $10 at H.C. Wainwright |
| December 1, 2025 11:34 am | Robert Burns | H.C. Wainwright | $10.00 | $8.04 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Nuvation Bio Inc (NUVB) |
| November 24, 2025 12:21 pm | — | Truist Financial | $11.00 | $6.99 | TheFly | Nuvation Bio initiated with a Buy at Truist |
| November 20, 2025 11:20 am | — | JMP Securities | $10.00 | $7.29 | TheFly | Nuvation Bio price target raised to $10 from $8 at Citizens JMP |
| November 4, 2025 10:45 am | — | JMP Securities | $8.00 | $5.17 | TheFly | Nuvation Bio price target raised to $8 from $6 at Citizens JMP |
| April 23, 2025 9:28 am | Silvan Tuerkcan | JMP Securities | $6.00 | $2.08 | TheFly | Nuvation Bio initiated with an Outperform at Citizens JMP |
Latest News for NUVB
200,000 Class A shares were sold for a transaction value of `$904,000 at around $4.52 per share on April 6, 2026. The sale accounted for 79.0% of Wentworth's direct Class A holdings, reducing direct ownership from 253,000 to 53,000 shares.
NEW YORK, April 07, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Nuvation Bio Inc. (NYSE: NUVB) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.
Capricorn Fund Managers Ltd bought a new position in shares of Nuvation Bio Inc. (NYSE: NUVB) in the undefined quarter, according to its most recent 13F filing with the SEC. The fund bought 1,588,854 shares of the company's stock, valued at approximately $14,236,000. Nuvation Bio accounts for approximately 3.4% of Capricorn Fund Managers
NEW YORK, April 2, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Nuvation Bio Inc. (NYSE: NUVB) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.
With acquisition of Japan rights, Nuvation Bio now has global development and commercialization rights for safusidenib Agreement provides Nuvation Bio ownership of global clinical development program, inclusive of clinical trials, past and current data generation, and future publications NEW YORK, April 1, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for NUVB.
U.S. House Trading
No House trades found for NUVB.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.